Reaction

Hepatic Mass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,897 reports · 64 co-occurring drugs

As of the last recalculation, Hepatic Mass appears in 1,897 FAERS reports alongside 64 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 29.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Octreotide Acetate	80	29.9	29.9
Ribociclib	81	29.4	29.4
Ado-Trastuzumab Emtansine	16	21.0	21.0
Exemestane	33	17.2	17.2
Goserelin	20	16.5	16.5
Fulvestrant	48	16.3	16.4
Alpelisib	12	15.2	15.2
Niraparib	29	14.5	14.6
Anastrozole Tablets	28	14.5	14.5
Lanreotide Acetate	9	12.6	12.7
Everolimus	52	11.5	11.5
Anastrozole	35	10.6	10.6
Regorafenib	11	10.5	10.5
Febuxostat Tablets 40 Mg	9	9.8	9.8
Febuxostat Tablets 80 Mg	9	9.8	9.8
Letrozole	53	9.7	9.7
Zoledronic Acid	34	9.4	9.5
Letrozole Tablets	40	9.3	9.3
Everolimus Tablets	14	9.2	9.2
Ledipasvir And Sofosbuvir	16	9.2	9.2
Ursosiol	16	9.1	9.1
Sorafenib	17	9.1	9.1
Rifaximin	17	9.0	9.0
Gemcitabine	31	8.8	8.8
Pazopanib Hydrochloride	21	8.6	8.6
Nebivolol	12	8.3	8.3
Ursodiol	16	8.1	8.1
Capecitabine	65	8.0	8.0
Sofosbuvir	14	7.8	7.8
Panitumumab	11	7.7	7.7
Gemcitabine Hydrochloride	32	6.7	6.7
Sitagliptin And Metformin Hydrochloride	13	6.7	6.7
Entecavir	7	6.6	6.6
Febuxostat	10	6.6	6.6
Atezolizumab	23	6.6	6.6
Tenofovir Disoproxil Fumarate Tablets	5	6.4	6.4
Imatinib Mesylate	16	6.3	6.3
Rucaparib	5	6.2	6.2
Erlotinib Hydrochloride	7	6.2	6.2
Trastuzumab	36	5.8	5.8
Erlotinib	5	5.7	5.7
Cisplatin	39	5.6	5.6
Bevacizumab	57	5.2	5.2
Naltrexone Hydrochloride And Bupropion Hydrochloride	4	5.2	5.2
Testosterone Cypionate	4	4.9	4.9
Ribavirin	28	4.8	4.8
Fluorouracil	33	4.7	4.7
Fluorouracil Cream, 0.5%	32	4.7	4.7
Avapritinib	5	4.5	4.5
Pertuzumab	11	4.5	4.5
Durvalumab	8	4.3	4.3
Velpatasvir And Sofosbuvir	5	4.3	4.3
Glecaprevir And Pibrentasvir	4	4.0	4.0
Temozolomide	7	3.7	3.7
Gefitinib	3	3.7	3.7
Tenofovir Disoproxil Fumarate	10	3.3	3.3
Abemaciclib	6	3.3	3.3
Drospirenone And Ethinyl Estradiol	13	3.2	3.2
Palbociclib	27	3.1	3.1
Axitinib	5	2.8	2.8
Apalutamide	3	2.8	2.8
Olaparib	5	2.6	2.6
Guselkumab	8	2.5	2.5
Osimertinib	7	2.4	2.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.